Your browser doesn't support javascript.
Demonstrating the Value of Collaboration
Pharmaceutical Technology Europe ; 33(3):44-45,48, 2021.
Article in English | ProQuest Central | ID: covidwho-20243755
ABSTRACT
[...]of the search for effective vaccines and treatments for COVID-19 being a priority, the development and manufacture of other treatments have been delayed, he adds. Through these industry collaborations, many developers have gained benefits, such as reduced time-to-market for new products, he specifies. [...]Quick believes that there will be more companies leaning towards outsourced services in the future, for development work and commercialization phases too. Given the disruption to the global pharmaceutical supply chain that has been experienced during the pandemic, O'Sullivan predicts that there will be opportunities for API suppliers in Europe, and elsewhere, to prosper from increased local demand, so long as the capacity and flexibility to deliver the required quantities are on available. [...]we will see significant investment by European API suppliers in expanded production capacity and capabilities in 2021 in order to attract Europe-based customers on the look-out for new local partners," he says. [...]Cruz emphasizes the rise of electronic health and customer records across Europe as an exciting prospect, particularly as it can lead to companies gaining a greater insight into treatments and customer needs.
Keywords
Search on Google
Collection: Databases of international organizations Database: ProQuest Central Type of study: Prognostic study Topics: Vaccines Language: English Journal: Pharmaceutical Technology Europe Year: 2021 Document Type: Article

Similar

MEDLINE

...
LILACS

LIS

Search on Google
Collection: Databases of international organizations Database: ProQuest Central Type of study: Prognostic study Topics: Vaccines Language: English Journal: Pharmaceutical Technology Europe Year: 2021 Document Type: Article